Sentences with phrase «cancer vaccine trial»

10/7/2008 Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine.

CRI: How did you learn about the cancer vaccine trial at Roswell Park?

«Based on the clinical evidence we've gathered over the past decade in our cancer vaccine trials,» Old said, «and in light of data from a variety of trials by others within the field, we believe therapeutic cancer vaccines will increasingly emerge as one of the safest and most powerful ways to combat a variety of cancers.»

Not exact matches

Now a new clinical trial is under way, by New York's Mount Sinai, to test a vaccine to combat recurrence in some of the most deadly forms of cancer, including lung, breast, gynecological and bladder cancers.

Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network; Past President and Director, Fred Hutchinson Cancer Research Center Dr. Diane Havlir, Professor of Medicine, University of California, San Francisco Moderator: Siobhan O'Connor, Time Magazine

BioNTech hit the headlines in July when its experimental personalized cancer vaccine, tailored to the tumors of individual patients, kept disease in check in an early - stage clinical trial.

Germany - based biotech companies CureVac and BioNTech are also testing several mRNA - based cancer vaccines in clinical trials.

Clinical trials testing various cancer vaccines have failed miserably; in one, a melanoma vaccine called Canvaxin did not improve the survival of patients, an outcome that ultimately forced the drugmaker to sell itself to another firm.

After phase III trials, reported in 2006, ended in disappointment for the prostate cancer vaccine Provenge (made by Dendreon in Seattle), subsequent analyses revealed that men whose prostate cancer had spread survived a median of 4.5 months longer than those given a placebo.

The FDA approved Merck's Gardasil vaccine in 2006, after clinical trials showed that it protects against four strains of human papillomavirus (HPV), which together cause about 70 percent of cervical cancers and 90 percent of genital warts.

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylcancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of PennsylCancer Center of the University of Pennsylvania.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

Tumors typically have a repertoire of molecular defenses they can use to suppress or evade immune attacks, which is why cancer vaccines and immunotherapies have had mixed results in clinical trials to date.

The German biotech CureVac, for example, has brought mRNA - based vaccines for rabies and cancer to clinical trials, and Karikó now heads a research team at BioNTech in Mainz, Germany, that focuses on mRNA - based drugs.

Trials of the vaccine therapy are planned to start later this year at Massachusetts General Hospital in Boston, Johns Hopkins Medical Center in Baltimore, the Queensland Institute of Medical Research (QIMR) in Brisbane and the Royal Netherlands Cancer Institute in Amsterdam.

«Additionally, this provides evidence needed to begin investigating a vaccine in human cancer clinical trials to determine whether genetically modified tumor cells producing IL - 15 and IL - 15Rα may induce anti-cancer responses.»

The extent of the benefit, she acknowledged, is not yet clear because the trial did not measure the vaccine's efficacy in preventing cancers.

Zheng and his colleagues became interested in annexin A2's exact role in cancer spread after noting a curious effect in a trial of the pancreatic cancer vaccine GVAX, first developed by Johns Hopkins researchers.

For example, although early clinical trials of Listeria - based vaccines have shown that the neutralized bacterium produces only mild flulike symptoms in human patients with cervical cancer, the various methods of genetically disarming the bacteria should be explored to find the safest approach for people gravely ill with pancreatic cancer, because these patients are likely to already have weak immune systems.

Due to major advances in their immune potency DNA vaccines are being studied in human clinical trials for treating cancer and infectious diseases.

A Vaccine against Epstein - Barr virus, which causes glandular fever and is implicated in several cancers, will start trials in people within a year.

Meanwhile, several biotech companies are launching trials combining neoantigen vaccines and checkpoint inhibitors for various cancers, including Neon Therapeutics in Cambridge, which Wu and Hacohen co-founded.

In a preliminary trial of an unconventional vaccine, several patients rid themselves of kidney cancer, a kind of cancer that is particularly hard to cure.

A new therapeutic vaccine, GTL001, developed by Genticel to clear HPV strains 16 and 18 — the types most likely to cause cancer — is being evaluated for safety in a Phase I clinical trial at the University of Louisville.

A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.

The latest data from a large clinical trial of Merck's cervical cancer vaccine, Gardasil, found it offered 100 % protection against cervical, vulval and vaginal diseases, caused by HPV (types 6, 11, 16 and 18) and 98 % protection against advanced pre-cancers caused by HPV types 16 and 18 (New England Journal of Medicine: vol 356, p1915).

Being both tumor - specific and widely expressed in human tumors, MAGE - A3 is an ideal cancer vaccine target and will be the focus of many clinical trials, including the largest clinical trial ever conducted in lung cancer, MAGRIT, launched by GlaxoSmithKline in 2007.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatment and of the need for continued public support for research to bring these treatments to more patients sooner.

The cancer vaccine is the first to show a survival benefit in a phase III trial, conferring a four - month overall survival advantage in men with advanced castrate - resistant prostate cancer.

Or if used in a vaccine, they may be most effective in combination with other drugs: a few patients in the small clinical trials whose cancer relapsed after the trials responded to treatment with a checkpoint inhibitor.

Along with the development of investigator initiated clinical trial concepts, the application of immunotherapies and cancer vaccines to clinical trials.

The trial was part of the Cancer Vaccine Collaborative, a joint program between the Cancer Research Institute and the Ludwig Institute for Cancer Research to develop therapeutic cancer vacCancer Vaccine Collaborative, a joint program between the Cancer Research Institute and the Ludwig Institute for Cancer Research to develop therapeutic cancer vacCancer Research Institute and the Ludwig Institute for Cancer Research to develop therapeutic cancer vacCancer Research to develop therapeutic cancer vaccancer vaccines.

Additional trials utilizing this vaccine are ongoing in glioblastoma, while a vaccine and checkpoint immunotherapy combination trial is being planned for patients with bladder cancer.

We have completed the active phase of a Phase 1 trial of a Vaxwave ® - based vaccine against cytomegalovirus (CMV) and are finalizing clinical development plans for TheraT ® in Human Papilloma Virus (HPV)- related head and neck cancers.

Some of these monoclonal antibodies are already available for clinical use and cancer vaccines are still undergoing clinical trials.

A new UC San Francisco study has shown that a cancer - killing («oncolytic») virus currently in clinical trials may function as a cancer vaccine — in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus - infected region.

Tags: aspirin, Bezos, bioengineering, Breast Cancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cCancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cCancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cCancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral ccancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral Vaccine and Infectious Disease, Vaccine development - Viral Vaccine development - Viral cancers

The new phase three study of the cervical cancer vaccine is needed for the FDA to consider approving it for more widespread use, said Ghamande, a principal investigator on the trial.

Before joining IDRI, Tracey worked as a Protocol Development Manager with the HIV Vaccine Trials Network at the Fred Hutchinson Cancer Research Center where she led multi-disciplinary teams in the design and implementation of clinical trials evaluating candidate HIV and tuberculosis vacTrials Network at the Fred Hutchinson Cancer Research Center where she led multi-disciplinary teams in the design and implementation of clinical trials evaluating candidate HIV and tuberculosis vactrials evaluating candidate HIV and tuberculosis vaccines.

A new pancreatic cancer vaccine being tested in clinical trials aims to restore the power of a patient's immune system.

WCBS 880 AM — A «Promising Lead» in Fight Against Pancreatic Cancer - April 4, 2012 Early results from a clinical trial at CINJ show stable disease in pancreatic cancer for certain candidates following vaccine treaCancer - April 4, 2012 Early results from a clinical trial at CINJ show stable disease in pancreatic cancer for certain candidates following vaccine treacancer for certain candidates following vaccine treatment.

In one eye - opening review of recent research, Charles Drake, M.D., Ph.D., of Johns Hopkins, who is also a member of CRI's clinical trials network, discussed several cancer vaccines that are making progress, including coxsackievirus A21, an oncolytic virus vaccine being studied in late stage melanoma, and NewLink's algenpantucel - L in pancreatic cancer (HyperAcute ® pancreas).

NJTV - New Pancreatic Study May Offer Hope for the Future - November 17, 2011 CINJ Deputy Director Dr. Edmund Lattime and Co-Director of CINJ's Gastrointestinal - Hepatobiliary Oncology Program Dr. Elizabeth Poplin discuss early results to a unique clinical trial that uses vaccine therapy to target pancreatic cancer.

In September 2015 Nick joined Moderna Therapeutics, a biotech startup in Cambridge, MA, where he and his team are bringing mRNA - based personalized cancer vaccines to clinical trials this year.

This vaccine prototype is today being studied by Cancer Center researchers in clinical trials for kidney, prostate, and pancreatic cancers.

More than a dozen experimental clinical therapies and vaccines have been developed from research from the Weiner laboratory, including the first Zika vaccine in clinical trials, as well as a novel immunotherapy for HPV - associated cancer and precancer.

March 29, 2018 - Scientists at Stanford University are currently preparing the first human test of a cancer «vaccine,» a treatment that eliminated up to 97 percent of tumors during trials with mice.

First, in 2001, CRI formed a partnership with the Ludwig Institute for Cancer Research to develop the Cancer Vaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production facilCancer Research to develop the Cancer Vaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production facilCancer Vaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production faciVaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production facilcancer vaccine production facivaccine production facilities.

A breast cancer vaccine developed at the School of Medicine is safe in patients with metastatic breast cancer, results of an early clinical trial indicate.

Most recently, CRI has launched a new «venture philanthropy» program called the Cancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical tCancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical tcancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical trials.